Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
NCT00461136
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes Type 2
Interventions
DRUG:
Aliskiren
Sponsor
Novartis